Rituximab biosimilar (Center of Molecular Immunology)

利妥昔单抗生物类似药 (Center of Molecular Immunology)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRituximab biosimilar (Center of Molecular Immunology)

Drug Alias NameMonoclonal anti CD20 chimeric antibody利妥昔单抗生物仿制药 (Center of Molecular Immunology)CIMAbiorRituxCIM

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsLymphoma, Non-Hodgkin

Approved Indications in ChinaN/A

Original Approved Country/TerritoryCuba

Original Approved Date2017/04/01

Country/TerritoryCuba

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesCenter Of Molecular Immunology

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeL01XC02